Christian S. Schade

2022

In 2022, Christian S. Schade earned a total compensation of $1.4M as Chairman and Chief Executive Officer at Aprea Therapeutics, a 58% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$281,500
Option Awards$581,672
Salary$328,417
Stock Awards$182,182
Total$1,373,771

Schade received $581.7K in option awards, accounting for 42% of the total pay in 2022.

Schade also received $281.5K in non-equity incentive plan, $328.4K in salary and $182.2K in stock awards.

Rankings

In 2022, Christian S. Schade's compensation ranked 2,419th out of 5,756 executives tracked by ExecPay. In other words, Schade earned more than 58.0% of executives.

ClassificationRankingPercentile
All
2,419
out of 5,756
58th
Division
Manufacturing
1,326
out of 3,133
58th
Major group
Chemicals And Allied Products
595
out of 1,419
58th
Industry group
Drugs
549
out of 1,320
58th
Industry
Pharmaceutical Preparations
397
out of 966
59th
Source: SEC filing on July 11, 2023.

Schade's colleagues

We found four more compensation records of executives who worked with Christian S. Schade at Aprea Therapeutics in 2022.

2022

Scott Coiante

Aprea Therapeutics

Chief Financial Officer

2022

Eyal Attar

Aprea Therapeutics

Chief Medical Officer

2022

Oren Gilad

Aprea Therapeutics

Chief Executive Officer

2022

Gregory Korbel

Aprea Therapeutics

Chief Operating Officer

News

You may also like